| 1 |
31866476 |
10.1016/j.semcancer.2019.12.008 |
2022 |
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. |
MTOR |
| 2 |
33782541 |
10.1038/s41401-021-00644-1 |
2022 |
SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma. |
MTOR |
| 3 |
33850273 |
10.1038/s41401-021-00643-2 |
2022 |
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. |
MTOR |
| 4 |
34074205 |
10.1080/15548627.2021.1936932 |
2022 |
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance. |
MTOR |
| 5 |
34162179 |
10.3324/haematol.2021.278743 |
2022 |
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas. |
MTOR |
| 6 |
34193976 |
10.1038/s41375-021-01326-x |
2022 |
Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice. |
MTOR |
| 7 |
34320785 |
10.3324/haematol.2021.278853 |
2022 |
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. |
MTOR |
| 8 |
34528236 |
10.1111/bjd.20760 |
2022 |
Transcriptomic changes during stage progression of mycosis fungoides. |
MTOR |
| 9 |
34624079 |
10.1182/blood.2021012081 |
2022 |
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. |
MTOR |
| 10 |
34670357 |
10.3324/haematol.2021.278796 |
2022 |
Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of <i>ex vivo</i> treated pediatric T-cell acute lymphoblastic leukemia cells. |
MTOR |
| 11 |
34673128 |
10.1016/j.canlet.2021.10.018 |
2022 |
Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds. |
MTOR |
| 12 |
34714908 |
10.1182/bloodadvances.2021005486 |
2022 |
Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. |
MTOR |
| 13 |
34791836 |
10.1002/cam4.4422 |
2022 |
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. |
MTOR |
| 14 |
34796518 |
10.1002/hon.2948 |
2022 |
Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T-cell acute lymphoblastic leukemia. |
MTOR |
| 15 |
34836490 |
10.1080/15548627.2021.1997053 |
2022 |
HYPK coordinates degradation of polyneddylated proteins by autophagy. |
MTOR |
| 16 |
34877904 |
10.1080/10428194.2021.2008382 |
2022 |
Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells. |
MTOR |
| 17 |
34913612 |
10.1002/cam4.4466 |
2022 |
miR-155-regulated mTOR and Toll-like receptor 5 in gastric diffuse large B-cell lymphoma. |
MTOR |
| 18 |
35019715 |
10.1128/jvi.01941-21 |
2022 |
Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties. |
MTOR |
| 19 |
35031886 |
10.1186/s43556-021-00066-9 |
2022 |
Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma. |
MTOR |
| 20 |
35033818 |
10.1016/j.bioorg.2022.105607 |
2022 |
Anti-leukemic effect and molecular mechanism of 11-methoxytabersonine from Melodinus cochinchinensis via network pharmacology, ROS-mediated mitochondrial dysfunction and PI3K/Akt signaling pathway. |
MTOR |
| 21 |
35035775 |
10.18632/oncotarget.28177 |
2022 |
GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells. |
MTOR |
| 22 |
35038545 |
10.1016/j.exphem.2022.01.004 |
2022 |
hnRNPK/Beclin1 signaling regulates autophagy to promote imatinib resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia cells. |
MTOR |
| 23 |
35053972 |
10.3390/foods11020240 |
2022 |
Protective Effect of <i>Ganoderma atrum</i> Polysaccharide on Acrolein-Induced Apoptosis and Autophagic Flux in IEC-6 Cells. |
MTOR |
| 24 |
35058488 |
10.1038/s41598-022-04916-6 |
2022 |
Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma. |
MTOR |
| 25 |
35064010 |
10.1136/jitc-2021-003766 |
2022 |
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. |
MTOR |
| 26 |
35068379 |
10.1080/16078454.2021.2019363 |
2022 |
Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma. |
MTOR |
| 27 |
35091546 |
10.1038/s41420-022-00833-9 |
2022 |
Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma. |
MTOR |
| 28 |
35091949 |
10.1007/s11356-022-18863-2 |
2022 |
Cadmium induces apoptosis and autophagy in swine small intestine by downregulating the PI3K/Akt pathway. |
MTOR |
| 29 |
35105670 |
10.1158/1541-7786.MCR-21-0729 |
2022 |
PARK2 regulates eIF4B-driven lymphomagenesis. |
MTOR |
| 30 |
35156211 |
10.1111/jfbc.14111 |
2022 |
Evaluation of the protective effects of morin against acrylamide-induced lung toxicity by biomarkers of oxidative stress, inflammation, apoptosis, and autophagy. |
MTOR |
| 31 |
35163615 |
10.3390/ijms23031693 |
2022 |
Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential. |
MTOR |
| 32 |
35174346 |
10.5187/jast.2021.e128 |
2022 |
Effect of hyperthermia on cell viability, amino acid transfer, and milk protein synthesis in bovine mammary epithelial cells. |
MTOR |
| 33 |
35184749 |
10.1186/s12885-022-09275-z |
2022 |
The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis. |
MTOR |
| 34 |
35188042 |
10.1080/10428194.2022.2042689 |
2022 |
Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. |
MTOR |
| 35 |
35191952 |
10.1158/1541-7786.MCR-21-0729 |
2022 |
PARK2 regulates eIF4B-driven lymphomagenesis. |
MTOR |
| 36 |
35219693 |
10.1016/j.exer.2022.109004 |
2022 |
Casein kinase I inhibitor D4476 influences autophagy and apoptosis in chloroquine-induced adult retinal pigment epithelial-19 cells. |
MTOR |
| 37 |
35220934 |
10.2174/1568009622666220225121009 |
2022 |
ND-16: A Novel Compound for Inhibiting the Growth of Cutaneous T Cell Lymphoma by Targeting JAK2. |
MTOR |
| 38 |
35237397 |
10.1177/20406207221080743 |
2022 |
Mantle cell lymphoma management trends and novel agents: where are we going? |
MTOR |
| 39 |
35248829 |
10.1016/j.redox.2022.102268 |
2022 |
mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells. |
MTOR |
| 40 |
35257981 |
10.1016/j.drup.2022.100822 |
2022 |
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. |
MTOR |
| 41 |
35259456 |
10.1016/j.cellsig.2022.110301 |
2022 |
Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL). |
MTOR |
| 42 |
35291908 |
10.1080/21655979.2022.2042142 |
2022 |
Protective effect of phillyrin against cerebral ischemia/reperfusion injury in rats and oxidative stress-induced cell apoptosis and autophagy in neurons. |
MTOR |
| 43 |
35304656 |
10.1007/s10565-022-09708-2 |
2022 |
Chemokine (C-X-C motif) ligand 1 maintains the immune surveillance function of natural killer cells via the PDK2/mTOR signaling pathway. |
MTOR |
| 44 |
35306048 |
10.1016/j.exphem.2022.03.005 |
2022 |
CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome. |
MTOR |
| 45 |
35321703 |
10.1186/s12906-022-03568-3 |
2022 |
Polyphenols in Ilex latifolia Thunb. inhibit human lung cancer cell line A549 by regulation of the PI3K-Akt signaling pathway. |
MTOR |
| 46 |
35336821 |
10.3390/biology11030449 |
2022 |
Post-Irradiation Thymic Regeneration in B6C3F1 Mice Is Age Dependent and Modulated by Activation of the PI3K-AKT-mTOR Pathway. |
MTOR |
| 47 |
35381283 |
10.1016/j.ijbiomac.2022.03.212 |
2022 |
Molecular characterization, expression and anti-tumor function analysis of yak IFITM2 gene. |
MTOR |
| 48 |
35397422 |
10.1016/j.bbrc.2022.03.105 |
2022 |
Poricoic acid A (PAA) inhibits T-cell acute lymphoblastic leukemia through inducing autophagic cell death and ferroptosis. |
MTOR |
| 49 |
35467473 |
10.1080/17474086.2022.2061455 |
2022 |
Advances in therapeutic strategies for primary CNS B-cell lymphomas. |
MTOR |
| 50 |
35483878 |
10.1101/mcs.a006188 |
2022 |
The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the <i>PIK3CA</i>-related megalencephaly-capillary malformation (MCAP) syndrome: a case report. |
MTOR |
| 51 |
35510955 |
10.15252/emmm.202215816 |
2022 |
A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability. |
MTOR |
| 52 |
35517800 |
10.3389/fphar.2022.875330 |
2022 |
Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives. |
MTOR |
| 53 |
35558005 |
10.1177/17588359221093745 |
2022 |
Novel insights into the biomarkers and therapies for primary central nervous system lymphoma. |
MTOR |
| 54 |
35571080 |
10.3389/fphar.2022.875016 |
2022 |
Anticancer Activities of <i>Polygonum odoratum</i> Lour.: A Systematic Review. |
MTOR |
| 55 |
35614940 |
10.3389/fphar.2022.875372 |
2022 |
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment. |
MTOR |
| 56 |
35625998 |
10.3390/cancers14102392 |
2022 |
Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality. |
MTOR |
| 57 |
35626685 |
10.3390/cells11101648 |
2022 |
SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta. |
MTOR |
| 58 |
35640776 |
10.1016/j.lfs.2022.120675 |
2022 |
Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis. |
MTOR |
| 59 |
35671182 |
10.1097/CM9.0000000000001916 |
2022 |
Hepatocyte growth factor protects pulmonary endothelial barrier against oxidative stress and mitochondria-dependent apoptosis. |
MTOR |
| 60 |
35674939 |
10.1007/s12032-022-01707-x |
2022 |
Pentacyclic triterpenoid ursolic acid induces apoptosis with mitochondrial dysfunction in adult T-cell leukemia MT-4 cells to promote surrounding cell growth. |
MTOR |
| 61 |
35688904 |
10.1007/s00277-022-04876-x |
2022 |
Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis. |
MTOR |
| 62 |
35713434 |
10.1097/MD.0000000000029312 |
2022 |
KIF23 is a potential biomarker of diffuse large B cell lymphoma: Analysis based on bioinformatics and immunohistochemistry. |
MTOR |
| 63 |
35730922 |
10.1080/10428194.2022.2086247 |
2022 |
SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma. |
MTOR |
| 64 |
35740513 |
10.3390/cancers14122847 |
2022 |
Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome. |
MTOR |
| 65 |
35743211 |
10.3390/ijms23126773 |
2022 |
Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF). |
MTOR |
| 66 |
35757978 |
10.1002/jbt.23117 |
2022 |
l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma. |
MTOR |
| 67 |
35774599 |
10.3389/fphar.2022.914733 |
2022 |
UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma. |
MTOR |
| 68 |
35774848 |
10.1155/2022/3276925 |
2022 |
Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. |
MTOR |
| 69 |
35785030 |
10.1155/2022/2253436 |
2022 |
Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. |
MTOR |
| 70 |
35810594 |
10.1016/j.bbrc.2022.06.089 |
2022 |
RHEB is a potential therapeutic target in T cell acute lymphoblastic leukemia. |
MTOR |
| 71 |
35857791 |
10.1080/15548627.2022.2100105 |
2022 |
Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis. |
MTOR |
| 72 |
35864538 |
10.1186/s13045-022-01315-2 |
2022 |
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype. |
MTOR |
| 73 |
35875136 |
10.3389/fonc.2022.913487 |
2022 |
Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia. |
MTOR |
| 74 |
35908982 |
10.1016/j.blre.2022.100992 |
2022 |
Follicular lymphoma: The long and winding road leading to your cure? |
MTOR |
| 75 |
35929918 |
10.1080/01443615.2022.2106834 |
2022 |
The effects of REG4 expression on chemoresistance of ovarian cancer. |
MTOR |
| 76 |
35981361 |
10.19746/j.cnki.issn.1009-2137.2022.04.012 |
2022 |
[Effect of Netrin-1 on VEGFA Expression in T-ALL Cells and Its Related Mechanism]. |
MTOR |
| 77 |
36029491 |
10.14715/cmb/2022.68.5.21 |
2022 |
Effects of Atractylon on Proliferation and Apoptosis of Intestinal Cancer Cells Through PI3K/AKT/mTOR Signaling Pathway. |
MTOR |
| 78 |
36051080 |
10.1002/jha2.535 |
2022 |
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma. |
MTOR |
| 79 |
32749680 |
10.1002/jcp.29943 |
2021 |
Light-emitting diode irradiation induces AKT/mTOR-mediated apoptosis in human pancreatic cancer cells and xenograft mouse model. |
MTOR |
| 80 |
32763229 |
10.1016/j.hemonc.2020.07.007 |
2021 |
Molecular events and cytotoxic effects of a novel thiosemicarbazone derivative in human leukemia and lymphoma cell lines. |
MTOR |
| 81 |
32800789 |
10.1016/j.pharmthera.2020.107659 |
2021 |
Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases. |
MTOR |
| 82 |
32898863 |
10.1182/blood.2020005622 |
2021 |
Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia. |
MTOR |
| 83 |
32970929 |
10.1111/ajco.13449 |
2021 |
Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. |
MTOR |
| 84 |
33037136 |
10.1158/1535-7163.MCT-19-0973 |
2021 |
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A. |
MTOR |
| 85 |
33044904 |
10.1080/15548627.2020.1821548 |
2021 |
BNIP3L/Nix-induced mitochondrial fission, mitophagy, and impaired myocyte glucose uptake are abrogated by PRKA/PKA phosphorylation. |
MTOR |
| 86 |
33154093 |
10.1158/1541-7786.MCR-20-0466 |
2021 |
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. |
MTOR |
| 87 |
33206174 |
10.1093/carcin/bgaa119 |
2021 |
Synergistic targeting of CHK1 and mTOR in MYC-driven tumors. |
MTOR |
| 88 |
33246167 |
10.1016/j.phrs.2020.105302 |
2021 |
Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities. |
MTOR |
| 89 |
33251904 |
10.1080/10428194.2020.1849679 |
2021 |
The regulation of bcr-abl in hypoxia is through the mTOR pathway. |
MTOR |
| 90 |
33300153 |
10.1002/hon.2831 |
2021 |
Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion. |
MTOR |
| 91 |
33311569 |
10.1038/s41417-020-00267-4 |
2021 |
LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma. |
MTOR |
| 92 |
33318657 |
10.1038/s41416-020-01205-9 |
2021 |
Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. |
MTOR |
| 93 |
33391513 |
10.7150/thno.46655 |
2021 |
LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma. |
MTOR |
| 94 |
33393503 |
10.1172/JCI133090 |
2021 |
BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors. |
MTOR |
| 95 |
33412518 |
10.18632/aging.202462 |
2021 |
Function of Deptor and its roles in hematological malignancies. |
MTOR |
| 96 |
33450375 |
10.1016/j.freeradbiomed.2020.12.452 |
2021 |
Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer. |
MTOR |
| 97 |
33475938 |
10.1007/s10637-021-01066-w |
2021 |
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. |
MTOR |
| 98 |
33484281 |
10.1007/s00109-020-02020-8 |
2021 |
3D culture conditions support Kaposi's sarcoma herpesvirus (KSHV) maintenance and viral spread in endothelial cells. |
MTOR |
| 99 |
33496749 |
10.1182/bloodadvances.2020002832 |
2021 |
Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop. |
MTOR |
| 100 |
33506273 |
10.1007/s00520-021-06016-z |
2021 |
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice. |
MTOR |
Datasets
Models
